Michael W. DeGregorio

Author

Also Known As

M DEGREGORIO, M DeGregorio, M W DeGregorio, M. DeGregorio, M. W. DeGregorio, M. W. Degregorio, M.W DeGregorio, Michael DeGregorio, Michael W DeGregorio, Michael W. DeGregorio

122

Publications

3.7K

Citations

H-Index

Concepts

All Affiliations

University of California, Davis University of California, San Francisco Cancer Research Institute Palmetto Hematology Oncology The University of Texas Health Science Center at San Antonio

About

Michael W. DeGregorio is an author at University of California, Davis specializing in pharmacology, medicine, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	47	1.8K
2	Health Sciences	8	8	218
3	Natural Sciences	1	1	143
4	Public Health	1	1	13
5	Allergy	1	1	75

Michael W. DeGregorio

Publications

2.7K

Citations

H-Index

Page 1

	Year	Citations
Fungal infections in patients with acute leukemia Michael W. DeGregorio, William M. F. Lee, Charles Linker, The American Journal of Medicine Acute LeukemiaClinical MycologyHematologyFungal Pathogen	1982	359
Acquired Tamoxifen Resistance: Correlation With Reduced Breast Tumor Levels of Tamoxifen and Isomerization of Trans-4-Hydroxytamoxifen C. Kent Osborne, Ester B. Coronado, D. Craig Allred, JNCI Journal of the National Cancer Institute Breast OncologyTamoxifen ResistanceMedicineTumor GrowthPharmacology	1991	235
Candida infections in patients with acute leukemia: Ineffectiveness of nystatin prophylaxis and relationship between oropharyngeal and systemic candidiasis Michael W. DeGregorio, William M. F. Lee, Curt A. Ries Cancer Translational MedicineAntibioticsCandida InfectionsAntifungal AgentsClinical Epidemiology	1982	159
Hyperthermic potentiation of cis-diamminedichloroplatinum(II) cytotoxicity in Chinese hamster ovary cells resistant to the drug. Kent E. Wallner, Michael W. DeGregorio, Gloria C. Li PubMed Medicinal ChemistryBiochemistryDdp ResistanceMedicineNatural Sciences	1986	143
Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. C. Kent Osborne, V. Wiebe, William McGuire, Journal of Clinical Oncology	1992	142
Toremifene: pharmacologic and pharmacokinetic basis of reversing multidrug resistance. Michael W. DeGregorio, James M. Ford, Constance Benz, Journal of Clinical Oncology New TriphenylethyleneMultidrug ResistancePharmacotherapyDrug ResistanceMolecular Pharmacology	1989	90
Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors. V. Wiebe, C. Kent Osborne, William McGuire, Journal of Clinical Oncology	1992	87
In vitro and in vivo biologic effects of Ospemifene (FC-1271a) in breast cancer Tracy L. Taras, Gregory T. Wurz, Michael W. DeGregorio The Journal of Steroid Biochemistry and Molecular Biology Tumor BiologyBreast OncologyOncologyVivo Biologic EffectsMedicine	2001	83
Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women Janne Komi, Kari S. Lankinen, Pirkko H rk nen, Menopause The Journal of The North American Menopause Society	2005	78
Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women Janne Komi, Kari S. Lankinen, Michael W. DeGregorio, Journal of Bone and Mineral Metabolism Bone DiseaseBiochemical MarkersBone HealthMedicineGynecology	2006	76

Page 1